Medication-induced weight gain and advanced therapies for the child with overweight and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement 2022

Cuda, Suzanne; Censani, Marisa; Kharofa, Roohi Y.; O'Hara, Valerie; Conroy, Rushika; Williams, Dominique R.; Paisley, Jennifer; Browne, Allen F.; Karjoo, Sara; Browne, Nancy T.

doi:10.1016/j.obpill.2022.100048

Cited by 12 publications

(42 citation statements)

References 142 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the use of antipsychotic medications, often prescribed for managing ASD symptoms, presents a risk factor for weight gain in this population. The medication linked to the most pronounced weight gain is olanzapine, followed with clozapine, risperidone, and aripiprazole, in ascending order of weight gain severity [ 56 ] ( Table 8 ).…”

Section: Discussionmentioning

confidence: 99%

Body Composition and Anthropometric Measurements in Children and Adolescents with Autism Spectrum Disorder: A Case–Control Study in Lebanon

Rouphael,

Sacre,

Bitar

et al. 2024

Nutrients

View full text Add to dashboard Cite

The occurrence of overweight and obesity among individuals with Autism Spectrum Disorder (ASD) has become a worldwide epidemic. However, there is limited research on this topic in the Lebanese population. Therefore, this study aimed to assess the differences in anthropometric measurements and body composition variables among Lebanese children, pre-adolescents, and adolescents diagnosed with ASD in contrast to typically developing peers across various developmental stages. Additionally, it aimed to investigate the prevalence of overweight and obesity within this population. A total of 86 participants with ASD and 86 controls were involved in this case–control study, conducted between June 2022 and June 2023. Anthropometric measurements and body composition variables were assessed, followed by statistical analyses to examine the differences between these two groups. The results revealed a significantly higher prevalence of overweight and obesity among individuals with ASD, particularly evident during childhood and pre-adolescence. Additionally, this group exhibited a higher body fat mass and total body fat percentage compared to controls. However, there were no significant differences observed between the two groups during adolescence. These findings emphasize the significance of monitoring and addressing weight status in individuals with ASD to improve their overall health outcomes. Future research directions could focus on investigating the underlying mechanisms contributing to the heightened prevalence of overweight and obesity in this population, ultimately enhancing their quality of life and well-being.

show abstract

Section: Discussionmentioning

confidence: 99%

Body Composition and Anthropometric Measurements in Children and Adolescents with Autism Spectrum Disorder: A Case–Control Study in Lebanon

Rouphael,

Sacre,

Bitar

et al. 2024

Nutrients

View full text Add to dashboard Cite

show abstract

“…The study excluded children under 5 years old or over 17 years old. The study excluded those receiving pharmacological treatment for obesity or obesity related complications based on the potential impact of health conditions and treatments that may influence food uptake among participants 22 .…”

Section: Materials/subjects and Methodsmentioning

confidence: 99%

Reduced plasma GDF10 levels are positively associated with cholesterol impairment and childhood obesity

Yousof,

Mejia-Benitez,

Morrison

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Childhood obesity is a global health concern affecting over 150 million children worldwide, with projections of a rise to 206 million by 2025. Understanding the mechanisms underlying this epidemic is crucial for developing effective interventions. In this study, we investigated circulating levels of Growth Differentiation Factor 10 (GDF10), a novel regulator of adipogenesis. Previous studies report diminished circulating GDF10 levels contribute to obesity and hepatic steatosis in mice. To further understand the role of plasma GDF10 in childhood obesity, a prospective case–control study was conducted. Using an enzyme-linked immunosorbent assay, plasma GDF10 levels were measured in children aged 5–17 years of age with normal (n = 36) and increased (n = 56) body mass index (BMI). Subsequently, plasma GDF10 levels were compared to various cardio-metabolic parameters. Children with increased BMI exhibit significantly lower levels of plasma GDF10 compared to children with normal BMI (p < 0.05). This study not only supports previous mouse data but is the first to report that lower levels of GDF10 is associated with childhood obesity, providing an important human connection for the relevance of GDF10 in obesity. Furthermore, this study revealed a significant correlation between low plasma GDF10 levels and elevated LDL-cholesterol and total cholesterol levels dependent on BMI (95% CI, p < 0.05). This study supports the hypothesis that children with obesity display lower plasma levels of GDF10, which correlates with elevated cholesterol levels. These insights shed light on potential mechanisms contributing to childhood obesity and may lead to future therapeutic interventions targeting GDF10 to mitigate adverse effects of adipogenesis in cardiometabolic health.

show abstract

“…For adolescents with SHCN and significant increase in hunger or lack of satiety, choosing anti-obesity medications (AOM) targeting these phenotypes is useful [ 49 ]. Common pharmacotherapy choices include phentermine, topiramate, GLP-1 receptor agonists (GLP-1 RAs), and naltrexone.…”

Section: The Adolescent With Special Healthcare Needs and Obesitymentioning

confidence: 99%

“…Common pharmacotherapy choices include phentermine, topiramate, GLP-1 receptor agonists (GLP-1 RAs), and naltrexone. Food craving and food seeking are targeted with topiramate and/or naltrexone [ 46 , 49 ]. GLP-1 RAs address multiple targets and are considered in patients with dysregulation of multiple phenotypes.…”

Section: The Adolescent With Special Healthcare Needs and Obesitymentioning

confidence: 99%

Special considerations for the adolescent with obesity: An obesity medicine association (OMA) clinical practice statement (CPS) 2024

Cuda,

O'Hara,

Censani

et al. 2024

Obesity Pillars

Self Cite

View full text Add to dashboard Cite

Medication-induced weight gain and advanced therapies for the child with overweight and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement 2022

Cited by 12 publications

References 142 publications

Body Composition and Anthropometric Measurements in Children and Adolescents with Autism Spectrum Disorder: A Case–Control Study in Lebanon

Body Composition and Anthropometric Measurements in Children and Adolescents with Autism Spectrum Disorder: A Case–Control Study in Lebanon

Reduced plasma GDF10 levels are positively associated with cholesterol impairment and childhood obesity

Special considerations for the adolescent with obesity: An obesity medicine association (OMA) clinical practice statement (CPS) 2024

Contact Info

Product

Resources

About